Literature DB >> 31085680

Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.

Wing-Chi G Yeung1, Nigel D Toussaint2,3, Sunil V Badve4,5.   

Abstract

Entities:  

Keywords:  chronic kidney disease; phosphate binders; randomized controlled trials

Mesh：

Substances：

Year:  2019        PMID： 31085680      PMCID： PMC6551782          DOI： 10.1681/ASN.2019040333

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  9 in total

Review 1.  Forging forward with 10 burning questions on FGF23 in kidney disease.

Authors:  Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 10.121

2.  Effects of phosphate binders in moderate CKD.

Authors:  Geoffrey A Block; David C Wheeler; Martha S Persky; Bryan Kestenbaum; Markus Ketteler; David M Spiegel; Matthew A Allison; John Asplin; Gerard Smits; Andrew N Hoofnagle; Laura Kooienga; Ravi Thadhani; Michael Mannstadt; Myles Wolf; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

3.  Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Authors:  Joachim H Ix; Tamara Isakova; Brett Larive; Kalani L Raphael; Dominic S Raj; Alfred K Cheung; Stuart M Sprague; Linda F Fried; Jennifer J Gassman; John P Middleton; Michael F Flessner; Geoffrey A Block; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2019-05-13       Impact factor: 10.121

4.  Cardiovascular effects of sevelamer in stage 3 CKD.

Authors:  Colin D Chue; Jonathan N Townend; William E Moody; Daniel Zehnder; Nadezhda A Wall; Lorraine Harper; Nicola C Edwards; Richard P Steeds; Charles J Ferro
Journal:  J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 10.121

5.  Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.

Authors:  Michael E Seifert; Lisa de las Fuentes; Marcos Rothstein; Dennis J Dietzen; Andrew J Bierhals; Steven C Cheng; Will Ross; David Windus; Víctor G Dávila-Román; Keith A Hruska
Journal:  Am J Nephrol       Date:  2013-08-07       Impact factor: 3.754

Review 6.  Nicotinamide and phosphate homeostasis in chronic kidney disease.

Authors:  Charles Ginsberg; Joachim H Ix
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

Review 7.  Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.

Authors:  Nigel D Toussaint; Eugenie Pedagogos; Sven-Jean Tan; Sunil V Badve; Carmel M Hawley; Vlado Perkovic; Grahame J Elder
Journal:  Nephrology (Carlton)       Date:  2012-07       Impact factor: 2.506

8.  Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study.

Authors:  Joachim H Ix; Michael G Shlipak; Christina L Wassel; Mary A Whooley
Journal:  Nephrol Dial Transplant       Date:  2009-12-27       Impact factor: 5.992

9.  Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.

Authors:  Nicole Lioufas; Nigel D Toussaint; Eugenia Pedagogos; Grahame Elder; Sunil V Badve; Elaine Pascoe; Andrea Valks; Carmel Hawley
Journal:  BMJ Open       Date:  2019-02-21       Impact factor: 2.692
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.